Semax is part of the FDA advisory committee peptide discussion set.
Evidence level: Primary regulatory
Sources: U.S. Food and Drug Administration
Use this as the page anchor until more sources are reviewed.
Research peptide
Semax
Semax is often discussed online in cognitive and performance contexts. The index treats it as a source-backed watch item until regulatory and primary-source records are reviewed.
Regulatory watch
Last reviewed 2026-06-30
Next review 2026-07-24
Evidence snapshot
Do not expand online cognitive claims without specific source support and review notes.
Scheduled for FDA advisory committee discussion in July 2026.
Frequently discussed in media and community contexts.
Needs claim-level source mapping before broader coverage.
Tracked claims
Sources on this page
Source records are stored in the repo and linked from each claim.
July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting
FDA advisory committee meeting notice listing multiple peptide bulk substances scheduled for discussion.
Certain bulk drug substances for use in compounding may present significant safety risks
FDA page summarizing bulk drug substances that may present significant safety risks in compounding contexts.